• Pharmaceutical Companies Receive FCPA Warning
  • November 18, 2009 | Authors: John E. Kelly; Anne Elkins Murray; Richard C. Smith
  • Law Firm: Fulbright & Jaworski L.L.P. - Washington Office
  • Pharmaceutical companies received a stern warning on Thursday: the Department of Justice (“DOJ”) is turning its Foreign Corrupt Practices Act (“FCPA”) focus to the pharmaceutical industry. With over 120 ongoing FCPA investigations and new resources being allocated by the DOJ and Securities and Exchange Commission (“SEC”) to FCPA enforcement, the message should not be taken lightly.